These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 23568603)

  • 1. Localized skin necrosis by bevacizumab.
    Frances L; Guijarro J; del Carmen Leiva-Salinas M; Albares MP; Ramon R
    Eur J Dermatol; 2013 Apr; 23(2):251-2. PubMed ID: 23568603
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
    Sathornsumetee S; Cao Y; Marcello JE; Herndon JE; McLendon RE; Desjardins A; Friedman HS; Dewhirst MW; Vredenburgh JJ; Rich JN
    J Clin Oncol; 2008 Jan; 26(2):271-8. PubMed ID: 18182667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ulceration of abdominal striae distensae (stretch marks) in a cancer patient.
    Dosal J; Handler MZ; Ricotti CA; Vega J; Tosti A; Kerdel FA
    Arch Dermatol; 2012 Mar; 148(3):385-90. PubMed ID: 22431783
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab plus irinotecan in recurrent glioblastoma.
    Chamberlain MC
    J Clin Oncol; 2008 Feb; 26(6):1012-3; author reply 1013. PubMed ID: 18281677
    [No Abstract]   [Full Text] [Related]  

  • 5. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.
    Gerstner ER; Frosch MP; Batchelor TT
    J Clin Oncol; 2010 Feb; 28(6):e91-3. PubMed ID: 19933906
    [No Abstract]   [Full Text] [Related]  

  • 6. [An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab].
    Dehais C; Souvannavong V; Nguyen BK; Jouniaux-Delbez N; Golmard JL; Tadrist C; Liou A; Delattre JY
    Rev Neurol (Paris); 2011 Nov; 167(11):841-6. PubMed ID: 21514945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.
    Fellah S; Girard N; Chinot O; Cozzone PJ; Callot V
    J Clin Oncol; 2011 Apr; 29(11):e308-11. PubMed ID: 21263101
    [No Abstract]   [Full Text] [Related]  

  • 8. Localized skin necrosis of steroid-induced striae distensae: an unusual complication of bevacizumab and irinotecan therapy.
    Fourcade S; Gaudy-Marqueste C; Tasei AM; Richard MA; Grob JJ
    Arch Dermatol; 2011 Oct; 147(10):1227-8. PubMed ID: 22006149
    [No Abstract]   [Full Text] [Related]  

  • 9. Primary brain tumors: introduction.
    Aiken RD; Byrne RW
    Semin Oncol; 2014 Aug; 41(4):437. PubMed ID: 25173136
    [No Abstract]   [Full Text] [Related]  

  • 10. Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.
    Dahan L; Ciccolini J; Evrard A; Mbatchi L; Tibbitts J; Ries P; Norguet E; Mercier C; Iliadis A; Ouafik L; Lacarelle B; Seitz JF
    J Clin Oncol; 2012 Feb; 30(4):e41-4. PubMed ID: 22184401
    [No Abstract]   [Full Text] [Related]  

  • 11. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
    Lou E; Turner S; Sumrall A; Reardon DA; Desjardins A; Peters KB; Sampson JH; Friedman HS; Vredenburgh JJ
    J Clin Oncol; 2011 Oct; 29(28):e739-42. PubMed ID: 21900098
    [No Abstract]   [Full Text] [Related]  

  • 12. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
    Zhang G; Huang S; Wang Z
    J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
    Chamberlain MC
    Neurology; 2010 Jan; 74(2):181. PubMed ID: 20065257
    [No Abstract]   [Full Text] [Related]  

  • 14. Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
    Garant A; Des Groseilliers S; Martin L; Ferland É; Vuong T
    Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):497-8. PubMed ID: 21576010
    [No Abstract]   [Full Text] [Related]  

  • 15. First description of an uterine perforation potentially imputable to treatment with bevacizumab.
    Uguen T; Leconte B; Desgrippes R; Tchoundeu B; Bretagne JF; Manfredi S
    Acta Oncol; 2012 Nov; 51(8):1102-4. PubMed ID: 23020310
    [No Abstract]   [Full Text] [Related]  

  • 16. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
    Bautista F; Paci A; Minard-Colin V; Dufour C; Grill J; Lacroix L; Varlet P; Valteau-Couanet D; Geoerger B
    Pediatr Blood Cancer; 2014 Jun; 61(6):1101-3. PubMed ID: 24375920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
    Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
    Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
    Kilickap S; Oztoprak I; Yucel B
    Acta Oncol; 2012 Apr; 51(4):544-6. PubMed ID: 22201408
    [No Abstract]   [Full Text] [Related]  

  • 19. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
    Wagner L; Turpin B; Nagarajan R; Weiss B; Cripe T; Geller J
    Pediatr Blood Cancer; 2013 Sep; 60(9):1447-51. PubMed ID: 23630159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
    Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
    Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.